Oppenheimer Reiterates Outperform Rating on Adverum Biotechnologies (ADVM)

October 3, 2024 9:21 AM EDT Send to a Friend
Oppenheimer analyst Francois Brisebois reiterated an Outperform rating and $28.00 price target on Adverum Biotechnologies (NASDAQ: ADVM).The analyst commented: "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login